IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab. - Wikidata - awgldk - TriplyDB

IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.

IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.

http://www.wikidata.org/entity/Q34605283

about

Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease Current stage in inflammatory bowel disease: What is next?Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease Role of CARD15, DLG5 and OCTN genes polymorphisms in children with inflammatory bowel diseases.Predicting response to Anti-TNF Agents for the treatment of crohn's disease.Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation.Protein therapeutics: new applications for pharmacogenetics.Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine.Clinical pharmacokinetics and use of infliximab.How does genotype influence disease phenotype in inflammatory bowel disease?Pharmacogenomics in dermatology: from susceptibility genes to personalized therapy.Pharmacogenomics in the treatment of inflammatory bowel disease.Genetic and genomic predictors of anti-TNF response.The role of pharmacogenetics in nonmalignant gastrointestinal diseases.Current relevance of pharmacogenetics in immunomodulation treatment for Crohn's disease.Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.Can We Predict the Efficacy of Anti-TNF-α Agents?Response to medical treatment in patients with Crohn's disease: the role of NOD2/CRAD15, disease phenotype, and age of diagnosis.Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.Therapeutic drug monitoring of anti-TNF therapy in children with inflammatory bowel disease.Inflammatory bowel disease: towards a personalized medicine.Prevalence of SLC22A4 1672T and SLC22A5 -207C combination defined TC haplotype in Hungarian ulcerative colitis patients.IGR2096a_1 T and IGR2198a_1 C alleles on IBD5 locus of chromosome 5q31 region confer risk for Crohn's disease in Hungarian patients.Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases Contribution of IBD5 Locus to Clinical Features of IBD Patients Haplotype in the IBD5 region is associated with refractory Crohn’s disease in Slovenian patients and modulates expression of the SLC22A5 gene

P2860

Q26745721-89CE356C-9A31-4E45-98D3-32C3C0A6C5BD Q26777429-DC541781-824D-46D7-9E7E-E7A2C15A838B Q33927688-9D8BE48C-16F1-4665-904B-5A17195C79E1 Q34099542-4720D1FB-7803-443D-AA9D-F7630BF51F62 Q34408990-6C399218-366D-4C22-81B7-D8D7CCE98EF5 Q36285782-AE9BA243-174D-4316-B183-63B20FF07A90 Q36501235-FE217A03-9441-4686-96E6-A48ED652F3D7 Q36642796-FF9396E2-357F-404C-AFD4-7357E74C7E33 Q36801108-79A7F700-2B13-4A89-AFDC-950B7EC0AA96 Q36892770-FF7F909F-FDFF-4E06-AF42-0AA5A1A58849 Q37038666-06D8FEB9-CDEA-47A3-94CC-A1D38686265F Q37434249-ACBC6908-D50F-4441-ABDB-E9A9EA4BD48F Q37710516-2CA5EE77-8B4F-4497-8475-677CE07025E7 Q37951648-F4F2A1DE-ACBE-4238-8329-7B6325965A5B Q37981892-40CFCF3A-1EC6-4BB0-9FF5-05EAB2A7882F Q38022258-EF0F62A5-8D8E-44A8-8805-758BB4A51529 Q38619950-BC1EE2F0-202F-4589-A967-8B5E8C756779 Q40594199-BE983889-3E91-487C-884C-75F8D64A7702 Q41122444-A73E4CDE-5DB9-4614-84D7-2346E353F5CC Q41660559-C9206B1D-197B-4819-B628-4263F8F34B23 Q43289269-1C9FFA1D-AFCF-4003-A70E-A3C91513530F Q43988900-CCDA2695-9337-430D-B789-26D4FF995998 Q48185411-5A3826EB-F2F6-4469-B060-EC7C1837EBEE Q49570157-671A6F09-5B47-47B9-BEC0-43A8B6471831 Q54179462-4D991473-D4AE-4ED4-991F-53F5B02C0DC9 Q54494742-40C33BD6-F7A8-4A4C-AB8E-84E5152F51CA Q57167308-CD939B29-215E-4544-983C-58CBF297B66A Q58193543-7B93B838-9639-4B69-9EEA-586BEC15B6FF Q58862202-C49E0C2F-A43E-4B92-B1FB-C57A31D24793

P2860

IBD5 polymorphisms in inflammatory bowel disease: association with response to infliximab.

http://www.wikidata.org/entity/Q34605283

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@ast

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@en

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@nl

type

label

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@ast

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@en

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@nl

prefLabel

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@ast

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@en

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@nl

P1433

Q34605283-4B9D1FAB-879F-44F6-AD12-094868373D10

P1476

Q34605283-157FF49E-9122-4A49-BB0C-C6783CD383A7

P2093

Q34605283-4C2C3788-0DF8-40D1-AF93-31ABA0ED587B

Q34605283-6CADF92C-2B09-4673-AF13-DCC85980AD25

Q34605283-7907A7AB-92DC-4372-A0A5-28BE90920B0A

Q34605283-971AE99A-FEF2-4D33-9A54-3E2F6F0BCC0C

Q34605283-A06F87C2-8CA9-4C92-AA35-F0DA0BE4FEC6

Q34605283-DAE52868-DC8C-47EB-8DC7-902DE865688B

Q34605283-F56E16A9-5C1F-4E8B-B791-C85FA286C6E7

P2860

Q34605283-10433D6B-28EB-4B09-904B-FAD870FBCDF9

Q34605283-1ECC0381-5EC7-4483-97E4-9A71C756CE92

Q34605283-22C6C40A-8D45-41FF-9B65-6DA2C8555316

Q34605283-3D1DABE6-C50B-45E4-BA87-9F2A3080035F

Q34605283-4DF5363C-ABE6-41B3-9B1F-E10482047139

Q34605283-53DDDDDA-B72B-4D94-AE65-82F4375F31D7

Q34605283-69936306-D404-426D-BCCA-25140DFF7B21

Q34605283-6B8E888E-6845-4B52-B6A0-0C794F3D8BBA

Q34605283-6C04C991-61F1-40C3-8F9A-EBE514341EB6

Q34605283-78E42303-27CF-4E0E-A5B4-EFF2D99A6931

P304

Q34605283-B21EF40A-3EB6-4DAF-8BB6-7B70E4AC380D

P31

Q34605283-3F953AD0-41D5-4FB1-A9FA-DC95559DC65B

P356

Q34605283-E0EE900A-07EC-4305-8DBF-2D4FC1748F99

P407

Q34605283-A1B43150-BB0F-4A88-8F86-3A8711EEA0C8

P433

Q34605283-ED5DF85C-EC36-4FAF-BAEE-59BEFD30F710

P478

Q34605283-6FEEAE20-75A0-46A1-98EE-DB34997ACB98

P577

Q34605283-CB00D6C2-2A38-4F4B-896F-C3E4171C2533

P5875

Q34605283-1BFDEE20-78EA-445F-A7AE-F47EE1C1B5BF

P698

Q34605283-A5E9A432-AF10-4C94-B0B0-0B4303CD144B

P921

Q34605283-89995153-4990-4395-9E8B-9B03EC5722BD

Q34605283-D1978957-AA34-4645-B0F5-F113ED6FEB93

P932

Q34605283-44CB411F-E2D3-446A-B854-87167DB79779

P356

WJG.V11.I8.1187

P1433

World Journal of Gastroenterology

P1476

IBD5 polymorphisms in inflamma ...... n with response to infliximab.

@en

P2093

Alfonso Martinez

http://www.w3.org/2001/XMLSchema#string

Carlos Taxonera

http://www.w3.org/2001/XMLSchema#string

Elena Urcelay

http://www.w3.org/2001/XMLSchema#string

Emilio-G de la Concha

http://www.w3.org/2001/XMLSchema#string

Juan-Luis Mendoza

http://www.w3.org/2001/XMLSchema#string

Laura Fernandez

http://www.w3.org/2001/XMLSchema#string

Manuel Diaz-Rubio

http://www.w3.org/2001/XMLSchema#string

P2860

A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease

Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Infliximab maintenance therapy for fistulizing Crohn's disease

Functional variants of OCTN cation transporter genes are associated with Crohn disease

NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses

Genetic evidence for interaction of the 5q31 cytokine locus and the CARD15 gene in Crohn disease.

IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis.

Human Nod1 confers responsiveness to bacterial lipopolysaccharides.

Familial occurrence of inflammatory bowel disease.

P304

1187-1192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V11.I8.1187

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7980617

http://www.w3.org/2001/XMLSchema#string

P698

15754402

http://www.w3.org/2001/XMLSchema#string

P921

inflammatory bowel diseases

P932

4250711

http://www.w3.org/2001/XMLSchema#string